Fisétine pour améliorer la fonction vasculaire chez les personnes âgées
Traduction clinique de la thérapie sénolytique avec la fisétine pour améliorer la fonction vasculaire chez les personnes âgées
This is a pilot clinical trial to test the efficacy of intermittent treatment with the flavonoid compound fisetin for improving vascular endothelial function and reducing aortic stiffness in older adults. This trial will also determine the potential mechanisms by which fisetin may improve vascular function, including by decreasing mitochondrial oxidative stress, cellular senescence and senescence-associated secretory phenotype (SASP) factors in circulation. Lastly, safety, tolerability and adherence of fisetin treatment will be assessed.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Cellular senescence increases with aging and contributes to physiological dysfunction. Studies in animal models show that the flavonoid compound fisetin is an effective treatment for reducing cellular senescence and improving vascular function with aging. No published studies have used fisetin to target cellular senescence in older adults to improve vascular function. In addition, the biological reasons (mechanisms) by which fistin may improve vascular function in older adults has not been assessed. This study will evaluate if intermittent treatment with fisetin in older adults improves vascular function, reduces biological markers of cellular senescence, oxidative stress and inflammatory factors produced by senescent cells (i.e., senescence-associated secretory phenotype factors). The study will also evaluate safety, tolerability and adherence with fisetin treatment.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Colorado
-
Boulder, Colorado, États-Unis, 80305
- University of Colorado Boulder
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 65 years or older
- Women must be postmenopausal
- Body mass index (BMI) <40 kg/m2
- Willing to accept random assignment
- Weight stable in the prior 2 months (<2 kg weight change) and willing to remain weight stable throughout the study
- Ability to understand study procedures and to comply with them for the entire length of the study
- No blood donation within 8 weeks prior to baseline testing; willingness to abstain from blood donation during the study and for 8 weeks after study completion
- Absence of established, serious, unstable, chronic clinical disease (e.g., unstable CVD) as determined by study physician of record based on subject medical history, physical examination, resting ECG and standard clinical blood chemistries
Exclusion Criteria:
- Inability to refrain from alcohol for 24 hours prior to outcome assessment
- Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with established senolytic effects) within 6 months prior to baseline testing; should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the subject by the PI
- New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)
- Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)
- Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing
- Inability or unwillingness of individual to give written informed consent
- Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study
- Known hypersensitivity or allergy to fisetin
- Blood donation within 2 months prior to baseline testing
- Resting blood pressure >160 mmHg systolic or >110 mmHg diastolic
- Regular vigorous aerobic/endurance exercise
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Fisetin
Fisetin will be administered in an intermittent manner with two, three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks. |
Fisetin dietary supplement |
|
Comparateur placebo: Placebo
Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with two, three-day dosing periods separated by two weeks. |
Placebo capsules identical in appearance to fisetin capsules |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in endothelial function at 1 month
Délai: 1 month
|
Brachial artery flow-mediated dilation |
1 month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in aortic stiffness at 1 month
Délai: 1 month
|
Carotid-femoral pulse wave velocity |
1 month
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in suppression of endothelial function by mitochondrial oxidative stress at 1 month
Délai: 1 month
|
Change in brachial artery flow-mediated dilation with acute, supratherapeutic MitoQ (160mg) |
1 month
|
|
Change from baseline in endothelial cell markers of cellular senescence at 1 month
Délai: 1 month
|
Endothelial cell abundance of p16 and p21 |
1 month
|
|
Change from baseline in blood cell markers of cellular senescence at 1 month
Délai: 1 month
|
p16-positive T-cells |
1 month
|
|
Change from baseline in plasma markers of the senescence-associated secretory phenotype
Délai: 1 month
|
Circulating pro-inflammatory cytokines and chemokines |
1 month
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Matthew J Rossman, PhD, University of Colorado, Boulder
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 23-0288
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .